St. Jude Augments AF Division With $47 Mil. Irvine Biomedical Purchase
This article was originally published in The Gray Sheet
Executive Summary
St. Jude will evaluate whether to pursue an atrial fibrillation indication for Irvine Biomedical, Inc.'s Therapy, Dual 8 and Cooled-Tip ablation catheters
You may also be interested in...
St. Jude Builds AF Strategy With $273 Mil. Endocardial Solutions Purchase
St. Jude Medical gains ablation catheter navigation technology to augment its atrial fibrillation portfolio under a $273 mil. acquisition of Endocardial Solutions
St. Jude Builds AF Strategy With $273 Mil. Endocardial Solutions Purchase
St. Jude Medical gains ablation catheter navigation technology to augment its atrial fibrillation portfolio under a $273 mil. acquisition of Endocardial Solutions
St. Jude Daig Division Splits To Emphasize Vascular Closure, AF Devices
Newly appointed president of St. Jude Medical's cardiology division Paul Buckman will work to retain AngioSeal's number-one position in the U.S. vascular closure device market as newcomer Abbott Labs tries to gain ground